biosimilar drugs cost

Top 3 factors in biosimilar coverageAn Avalere study has interesting findings about payer acceptance of biosimilars.
Business Group Makes Price Recommendations for Specialty Drugs
Business Group Makes Price Recommendations for Specialty DrugsThe high cost of specialty drugs demands a change in Washington, according to a report.
Can costs be contained?There’s a lot of blame to go around when it comes to why drug costs are rising in dermatology. We’ll let the research do the finger pointing.
Biosimilars uptake may lag for cancer patients, physiciansBiosimilars will have a significant impact on cancer treatment, with the potential to drive cost savings, but will patients and providers be accepting?
Biosimilars pose problems for Medicare beneficiaries
Biosimilars pose problems for Medicare beneficiariesSurprisingly, Medicare beneficiaries are likely to pay much more for biosimilars than the referenced brand medication, according to a new report.